Últimas noticias sobre Bread Finl Hldgs (NYSE:BFH) Bolsa

Bread Finl Hldgs

Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.

Bread Financial Holdings, Inc. Common Stock

Bread Financial Holdings Inc

BENEFICIAL HLDGS INC by Beneficial Holdings, Inc.

Beneficial Holdings Inc

WIIM

GSK shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance. Also, the company raised its FY25 sales guidance above estimates.

Wells Fargo analyst Ike Boruchow upgrades VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from Underweight to Equal-Weight and lowers the price target from $18 to $12.

News

Upgrades

Price Target

Analyst Ratings

Wells Fargo Upgrades VF to Equal-Weight, Lowers Price Target to $12

Eric Trump, executive vice president of the Trump Organization and the younger son of President Donald Trump, criticized the current financial system as outdated and inefficient, suggesting that cryptocurrency offers a faster and more cost-effective alternative. 
What Happened: Speaking this week in Dubai, he warned that traditional banks could become obsolete within the next decade if they fail to adapt.
In a thorough critique delivered during his visit to the UAE, which is an emerging hub for digital currencies, Trump called SWIFT "an absolute disaster." 
He said, "there's nothing that can be done on blockchain that can't be done better than the way that the current financial institutions are working," in a conversation <a href="https://www.cnbc.com/2025/04/30/eric-trump-if-banks-dont-watch-whats-coming-theyll-be-extinct-in-ten-years-.html">with</a> CNBC.
"The modern financial system is broken, it's slow, it's expensive," he said. "If the banks don't watch what's coming, they're going to be extinct in 10 years." He argued that decentralized finance allows for private, low-cost transactions and said that the U.S. banking system "favors the ultra-wealthy" and is politically weaponized.
To establish his point about the increasing irrelevance of banks, Trump said: "You can open up a DeFi app right now, you can open up any cryptocurrency app, and you can send money, wallet to wallet, instantaneously, without the expense, without the variability" of banks.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Eric Trump on cryptocurrency: Traditional banks risk going extinct" width="500" height="281" src="https://www.youtube.com/embed/cLnNedcVgcU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-this-is-the-type-of-stuff-you-might-expect-to-see-in-china">Trump&#8217;s Call To Jeff Bezos Over Amazon&#8217;s Tariff Display Earns Peter Schiff&#8217;s Ire: &#8216;Type Of Stuff You Might Expect To See In China&#8217;</a>
Why It Matters: Trump's remarks come at a time when major banks like <a href="https://www.jpmorgan.com/kinexys/index">JP Morgan</a> are creating blockchain platforms and crypto services to keep up with the rapid scale of digital transformation. His comments also coincide with increasing regulatory scrutiny of crypto markets after notable episodes of volatility and collapses.
Meanwhile, the Trump administration has fashioned itself as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43836911/trump-reiterates-resolve-to-make-us-the-crypto-capital-critic-labels-idea-of-bitcoin-reserve-legislation-absurd">champion of digital currencies</a>, and the Trump family is entangled with initiatives such as the <a href="https://www.benzinga.com/news/legal/25/04/45077156/trump-affiliated-world-liberty-financial-defies-ethics-concerns-raises-550-million">World Liberty Financial</a> and American Bitcoin.
Eric Trump's comments come just ahead of his father's scheduled trip to the Gulf from May 13 to 16, with stops in the UAE, Saudi Arabia, and Qatar. The visit will mark the first time a U.S. president has visited the Emirati sheikhdom since George W. Bush in 2008.
Trump, dubbed the &#8220;crypto president,&#8221; recently completed his first 100. While he delivered on his campaign promise to establish a national <a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise">Bitcoin Strategic Reserve</a>, funded with coins seized through asset forfeiture, the move hasn&#8217;t put a stop to Bitcoin's slide. The cryptocurrency, which hit an all-time high of $109,000 before Trump's inauguration, has since <a href="https://www.benzinga.com/25/04/45092876/bitcoin-sinks-13-in-trumps-first-100-days-but-do-you-remember-how-the-apex-crypto-fared-during-bidens-presidency">fallen more than 13%. </a>
Analysts attribute the decline to increasing economic turmoil catalyzed by Trump's aggressive tariff policies. Despite a brief rebound from a low of $76,000, Bitcoin remains far below its peak. 
Read Next: <a href="https://www.benzinga.com/news/earnings/25/04/45089879/paypal-says-buy-now-pay-later-users-spend-33-more-make-17-more-transactions-pushes-for-global-rollout" target="_blank" rel="noreferrer noopener">PayPal Says ‘Buy Now, Pay Later' Users Spend 33% More, Make 17% More Transactions—Pushes For Global Rollout</a>
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

General

Eric Trump Warns Banks Could Be 'Extinct In 10 Years' If They 'Don't Watch What's Coming,' Touting Blockchain As 'Better' Alternative

Wells Fargo analyst Ike Boruchow downgrades Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from Equal-Weight to Underweight and lowers the price target from $25 to $12.

Downgrades

VSCO

Wells Fargo Downgrades Victoria's Secret to Underweight, Lowers Price Target to $12

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-1024x576.jpg" alt="" class="wp-image-11905" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The world of crypto trading is undergoing a seismic transformation. What was once a volatile, sentiment-driven market is increasingly governed by machine learning models, sentiment analytics, and AI-optimized strategies. In 2025, the future of crypto isn't just decentralized it's automated. &nbsp;
Auto Trading bots have existed in traditional equity markets for many years, but AI has given them a new edge.
Institutional Traders Are All In on AI
Wall Street and other financial centers are not just watching from the sidelines. Major hedge funds and trading desks are deploying proprietary AI models that parse order book dynamics, social media sentiment, ETF flows, and macroeconomic data in milliseconds. These systems can adapt strategies in real time, optimizing execution without emotional bias.
What makes this shift significant is that it's narrowing the edge that once favored manual traders. The barrier to entry now lies in compute power and access to high-quality data , not just intuition or experience.
Retail Investors Enter the Algorithm Arms Race
Retail platforms are rapidly adapting. Analytics dashboards, and AI-enhanced bots on platforms are democratizing access to algorithmic trading. Users can now backtest strategies, monitor momentum signals, and integrate AI into their portfolios with minimal coding knowledge.
This evolution is creating a smarter retail segment investors who are data-driven, adaptive, and less prone to panic.
Volatility, Liquidity, and the New Normal
With algorithms responding instantly to news, tweets, and regulatory developments, crypto markets in 2025 exhibit micro-volatility which are short bursts of intense movement followed by rapid stabilization. Liquidity providers are increasingly automated as well, meaning spreads tighten faster but whipsaws are more common.
It's a new dynamic where speed and structure outweigh instinct and speculation.
The Future: AI Co-Pilots for Every Investor
Looking ahead, expect more AI "co-pilot" tools and systems that don't just execute trades but explain the reasoning behind them. These tools still require significant back testing to be generally accepted, but natural language interfaces will allow users to ask questions like, "Why did my portfolio shift from ETH to SOL?" and get algorithm-backed answers.
As the crypto ecosystem matures, AI isn't replacing traders—it's augmenting and upgrading them.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Disclosure:
The author does not hold any financial positions in the cryptocurrencies mentioned in this article and has no relevant affiliations with any companies discussed.
Author Bio:
Michael Collins is a veteran financial analyst with three decades of experience in equities, bonds, and macro strategy. He explores how technology is shaping investor behavior at <a href="https://www.cryptoflowzone.com">CryptoFlowZone.com</a>.

Opinion

The AI-Driven Future of Crypto Trading: How Algorithms Are Rewriting Market Strategies

Needham analyst James Ricchiuti maintains CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) with a Buy and raises the price target from $33 to $34.

CECO

Needham Maintains Buy on CECO Environmental, Raises Price Target to $34

COCO

Vita Coco shares are trading higher after the company reported better-than-expected Q1 financial results.

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –
– Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo –
– Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo –
– Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified –
– Webcast to be Held Today, April 30, at 8:00 am ET –
NEW YORK, April 30, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1233229441&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).

IMUX

Immunic Reports Data From Phase 2 CALLIPER Trial Of Nurr1 Activator, Vidofludimus Calcium, In Patients With Progressive Multiple Sclerosis

2025 Guidance
The Company is maintaining its full year financial guidance for 2025. Specifically, the company anticipates the following:
<ul>
<li>Core sales growth in the range of (0.5%) to +3.5% year-over-year</li>
<li>Adjusted EBITDA of $735 million to $795 million</li>
<li>Adjusted Earnings Per Share of $1.36 to $1.52</li>
<li>Capital Expenditures of approximately $120 million</li>
<li>Free Cash Flow conversion exceeding 90%</li>
</ul>
Share-based metrics in the Company's guidance do not include the effect of any potential share repurchases.

Guidance

GTES

Gates Industrial Affirms FY25 Outlook: Adj EPS Of $1.36-$1.52 Vs $1.42 Estimate; Sales Of $3.43B-$3.56B Vs $3.37B Estimate

Wells Fargo analyst Ike Boruchow upgrades Canada Goose Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#TSX">GOOS</a>) from Underweight to Equal-Weight and maintains the price target from C$11 to C$11.

TSX:GOOS

Wells Fargo Upgrades Canada Goose Hldgs to Equal-Weight, Maintains Price Target to C$11

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

Reiteration

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

<ul>
<li>Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study</li>
<li>Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits</li>
<li>Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients</li>
<li>Presence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04)</li>
<li>Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting clinical data from the pivotal Phase 3 study of its lead product candidate, Bria-IMT&#x2122;, in metastatic breast cancer (BRIA-ABC; <a href="https://www.globenewswire.com/Tracker?data=ybz8DVgm_DDXdomIc09Bnf5ZTBfx0sXWwOqyq2BDn6FG4IWGsMeybTqHsku7QDAwXhaGkSWKrU_L7SMWlA3laHcx91S8kWVPVgciXPJahzyL687kZvcgWSnx1Jv2uvAR">NCT06072612</a>) supporting the use of specific biomarkers to predict patients' clinical response to Bria-IMT treatments.

BCTX

TSX:BCT

Briacell Presents Clinical Data From Pivotal Phase 3 Study Of Bria-IMT, In Metastatic Breast Cancer Supporting Use Of Specific Biomarkers To Predict Patients' Clinical Response To Bria-IMT Treatments

First National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXNC#NASDAQ">FXNC</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.54 by 35.19 percent. This is a 31.37 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $21.06 million which missed the analyst consensus estimate of $22.00 million by 4.26 percent. This is a 41.38 percent increase over sales of $14.90 million the same period last year.

Earnings

Earnings Misses

FXNC

First National Q1 Adj. EPS $0.35 Misses $0.54 Estimate, Sales $21.06M Miss $22.00M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) with a Buy and raises the price target from $11 to $15.

NVCT

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Raises Price Target to $15

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $383 to $384. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Visa shares closed at $341.52 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/V/analyst-ratings">view this stock</a>.</li>
<li>TD Securities cut the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $102 to $90. TD Securities analyst Agnes Lim maintained a Buy rating. Starbucks shares closed at $84.85 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">view this stock</a>.</li>
<li>Needham cut AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $51 to $44. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $34.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">analysts view this stock</a>.</li>
<li>DA Davidson cut the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $170 to $155. DA Davidson analyst Tom White upgraded the stock from Neutral to Buy. Airbnb shares closed at $125.49 on Tuesday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from $105 to $90. JP Morgan analyst Tami Zakaria downgraded the stock from Overweight to Neutral. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) price target from $25 to $9. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. NeoGenomics shares settled at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) price target from $12 to $8. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) price target from $15 to $8. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Zynex shares closed at $2.23 on Tuesday.  <a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup lowered the price target for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from $23 to $19. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Warby Parker shares settled at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank increased T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) price target from $275 to $277.5. Scotiabank analyst Maher Yaghi upgraded the stock from Sector Perform to Sector Outperform. T-Mobile US shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png" alt="" class="wp-image-894667" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ABNB

ATRC

PCAR

QTRX

SBUX

TMUS

WRBY

ZYXI

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Wells Fargo analyst Ike Boruchow downgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Overweight to Equal-Weight and lowers the price target from $75 to $55.

Wells Fargo Downgrades Nike to Equal-Weight, Lowers Price Target to $55

Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.&nbsp;

CNTX

Context Therapeutics Presents New Preclinical Data for Solid Tumor Therapy at Major Cancer Conference

Clean Harbors Co-CEO Gerstenberg Says, "we recognize that we are operating in a period of uncertainty regarding U.S. policies on trade and tariffs, and the larger implications for the overall economy. We have taken steps around pricing to offset the additional costs we anticipate from tariffs and have not seen a reduction in demand for our core services. As a result, we are maintaining our Adjusted EBITDA and adjusted free cash flow guidance."

V2X Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) announced it has been awarded a new five-year task order to support U.S. Space Force operations at Ascension Island as part of the U.S. Air Force's Contract Augmentation Program V (AFCAP V). The firm-fixed-price award includes a one-year base period and four one-year option periods, with a ceiling value of $140 million.

V2X Awarded $140M, 5-Yr Task Order To Support U.S. Space Force Operations At Ascension Island As Part Of U.S. AFCAP V

Stock Split

Caliber Announces 1-for-20 Reverse Stock Split Effective May 2, 2025

Press Releases

Bread Financial to Participate in the 2025 RBCCM Global Financial Institutions Conference

Financing

Bread Financial Announces Private Offering of Subordinated Notes

Bread Financial Announces Approval of $150 Million Share Repurchase Program

Bread Financial Announces Pricing of Private Offering of $400 million of Subordinated Notes

Bread Financial Provides Performance Update for February 2025

Bread Financial Schedules First Quarter 2025 Earnings Conference Call for Apr. 24

Dividends

Bread Financial Declares Dividend on Common Stock

Bread Financial Reports First Quarter 2025 Results

Crypto.com Selects Bread Financial to Launch New Crypto-based Rewards Credit Card Program in the U.S.

Bread Financial Provides Performance Update for March 2025

Ally Financial

American Express

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Financial servs

Encore Capital Gr

Enova International

EZCORP, Inc. - Class A Non-Voting Common Stock

EZCORP

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Group

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Comments

Bread Finl Hldgs

Noticias

Últimas noticias sobre Bread Finl Hldgs (NYSE:BFH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL